BGI Joins with Clearbridge BioMedics to Develop Liquid Biopsy in China
publication date: May 17, 2016
BGI, the Shenzhen "omics" company, has partnered with Singapore's Clearbridge BioMedics to distribute and develop its liquid biopsy product in greater China. CBB's ClearCell®
FX1 product separates circulating tumor cells (CTC) from the blood. BGI intends to use its expertise, which stretches from genomics to trans-omics, to develop a product that provides clinical insights from a blood draw for clinical and research use, furthering personalized medicine. The machine adds to BGI's offerings in the clinical diagnostics market. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.